乳腺癌中Ki-67、EGFR及E-cad表达及其对预后的影响研究

doi:10.3760/cma.j.issn.1007-1245.2022.11.002

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (11): 1486-1491.DOI: 10.3760/cma.j.issn.1007-1245.2022.11.002

乳腺癌中Ki-67、EGFR及E-cad表达及其对预后的影响研究

程辰¹ 李雪平² 徐艺³ 赵红艳¹ 赵海涛⁴

¹连云港市中医院超声科，连云港　222004； ²连云港市第一人民医院超声科，连云港　222000； ³连云港市第一人民医院药学部，连云港　222000； ⁴连云港市中医院普外科，连云港　222004

收稿日期:2022-04-13 出版日期:2022-06-01 发布日期:2022-06-15
通讯作者: 赵红艳，Email：643627734@qq.com
基金资助:
连云港重点研发计划（社会发展）项目（SF2112）；

连云港市中医院"赵化南"青年科技基金项目（Lzyq2106）

Expressions of Ki-67, EGFR, and E-cad in breast cancer and their effects on prognosis

Cheng Chen¹, Li Xueping², Xu Yi³, Zhao Hongyan¹, Zhao Haitao⁴

¹Department of Ultrasound, Lianyungang Hospital of Traditional Chinese Medicine, Lianyungang 222004, China; ²Department of Ultrasound, Lianyungang First People's Hospital, Lianyungang 222000, China; ³Department of Pharmacy, Lianyungang First People's Hospital, Lianyungang 222000, China; ^{4 Department of General Surgery, Lianyungang Hospital of Traditional
Chinese Medicine, Lianyungang 222004, China}

Received:2022-04-13 Online:2022-06-01 Published:2022-06-15
Contact: Zhao Hongyan, Email: 643627734@qq.com
Supported by:
Project of Lianyungang Key R&D Program (Social Development) (SF2112);

Project Supported by Zhao Huanan's Youth Science and Technology Fund at Lianyungang Hospital of Traditional Chinese Medicine (Lzyq2106)

摘要/Abstract

摘要： 目的　探讨乳腺癌中细胞增殖相关抗原（Ki-67）、表皮生长因子受体（EGFR）和上皮钙黏附蛋白（E-cad）表达及其对预后的影响。方法　回顾性研究2015年5月至2021年12月连云港市第一人民医院及连云港市中医院经手术切除的乳腺癌标本167例，随访并整理患者病例资料，运用SPSS 24.0软件进行统计学分析，计数资料的组间比较采用卡方检验，采用Spearman分析评价生物学预后因子与临床病理特征、预后评价体系Neo-bioscore相关性的研究；总生存期、生存分析观察采用Kaplan-Meier法进行单因素分析并绘制生存曲线；采用Cox回归模型开展多因素分析，进一步排除混杂因素所产生的影响。结果　乳腺癌标本167例，其患者平均年龄为46.4岁。（1）乳腺癌患者的病理分子分型与Ki-67、EGFR表达差异均有统计学意义（χ²=30.463、P<0.001，χ²=25.652、P<0.001）；Ki-67与EGFR，EGFR与E-cad之间的表达水平，差异均有统计学意义（χ²=7.167、P=0.007，χ²=18.576、P<0.001）。（2）EGFR与Ki-67的表达水平有紧密的正相关性（r=0.207，P=0.007），与E-cad的表达水平有显著的负相关性（r=-0.325，P<0.001）；乳腺癌Neo-bioscore评分体系分值高低与Ki-67、EGFR的表达水平均呈正相关性（r=0.324、P<0.001，r=0.176、P=0.023），与E-cad的表达水平呈负相关性（r=-0.162，P=0.037）。（3）通过Kaplan-Meier单因素及COX模型多因素生存分析显示：乳腺癌患者的Ki-67表达水平和Neo-bioscore评分是影响乳腺癌预后的因素（χ²=3.950、P=0.047，χ²=13.372，P=0.004），且为影响乳腺癌患者生存的独立危险因素。结论　Ki-67、EGFR及E-cad表达对增殖活性分子表达等产生了辅助判断作用，使得个性化、靶向治疗成为可能，与乳腺癌患者的预后有直接或间接相关性，动态监测肿瘤靶向治疗效果，从而更好地为临床服务。

关键词: 乳腺癌, Ki-67, EGFR, E-cad, 生存分析

Abstract: Objective　To investigate the expressions of Ki-67, EGFR, and E-cad in breast cancer and their effects on prognosis. Methods　One hundred and sixty-seven breast cancer specimens from Lianyungang First People's Hospital and Lianyungang Hospital of Traditional Chinese Medicine between May 2015 and December 2021 were retrospectively studied. The patients were followed up, and their data were sorted out. The SPSS 24.0 software was used for statistical analysis. The chi-square test was used to compare the enumeration data between the groups. Spearman analysis was used to evaluate the correlation of biological prognostic factors with clinicopathological characteristics and the Neo-bioscore prognostic evaluation system. The overall survival and survival analysis were observed by the Kaplan-Meier method. Single factor analysis was performed, and the survival curves were drawn. Cox regression model was used to carry out multivariate analysis to further exclude the influence of confounding factors. Results　The patients was averagely 46.4 years old. The pathological molecular typing of breast cancer was significantly different from the expressions of Ki-67 and EGFR (χ²=30.463, P<0.001; χ²=25.652, P<0.001); there were statistical differences between the expressions of Ki-67 and EGFR and between the expressions of EGFR and E-cad (χ²=7.167, P=0.007; χ²=18.576, P<0.001). There was a close positive correlation between the expression levels of EGFR and Ki-67 (r=0.207, P=0.007), and a negative correlation between the expression levels of EGFR and E-cad (r=-0.325, P<0.001); the Neo-bioscore score of breast cancer was positively correlated with the expression levels of Ki-67 and EGFR (r=0.324, P<0.001; r=0.176, P=0.023), and negatively with the expression level of E-cad (r=-0.162, P=0.037). The Kaplan-Meier univariate and COX model multivariate survival analysis showed that the Ki-67 expression level and Neo-bioscore score of breast cancer were the prognostic factors of breast cancer (χ²=3.950, P=0.047; χ²=13.372, P=0.004), and were the independent risk factors affecting the survival of breast cancer patients. Conclusions　The expressions of Ki-67, EGFR, and E-cad have an auxiliary judgment effect on the expressions of proliferative active molecules, making personalized and targeted therapy possible, and have a direct or indirect correlation with the prognosis of breast cancer patients. Dynamically monitoring the effect of tumor-targeted therapy has better clinical service.

Key words: Breast cancer, Ki-67, EGFR, E-cad, Survival analysis

程辰, 李雪平, 徐艺, 赵红艳, 赵海涛. 乳腺癌中Ki-67、EGFR及E-cad表达及其对预后的影响研究[J]. 国际医药卫生导报, 2022, 28(11): 1486-1491.

Cheng Chen, Li Xueping, Xu Yi, Zhao Hongyan, Zhao Haitao. Expressions of Ki-67, EGFR, and E-cad in breast cancer and their effects on prognosis[J]. International Medicine and Health Guidance News, 2022, 28(11): 1486-1491.

参考文献

[1] Jain KK. Biomarkers of Cancer[M].The Handbook of Biomarkers. Clifton, Passaic County: Humana Press, Inc, 2017.

[2] 马飞,徐兵河,邵志敏.乳腺癌随访及伴随疾病全方位管理指南[J].中华肿瘤杂志,2019,41(1):29-41.DOI:10.3760/cma.j.issn.0253-3766.2019.01.010.

[3] Zhang JT, Zhao BC, Jin F. The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: the analytic results from the SEER database[J]. the breast journal,2019,25(5):838-847. DOI:10.1111/tbj.13347.

[4] Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35[J]. Cancer, 2003, 97(1):134-147. DOI: 10.1002/cncr.11051.

[5] 李贺,左婷婷,曾红梅,等.不同年龄女性乳腺癌患者的临床特征及预后分析[J].中华肿瘤杂志,2021,43(1):126-131.DOI:10.3760/cma.j.cn112152-20191212-00801.

[6] Yu J, Li Y, Li X, et al. Real-world clinical analysis and overall survival-related biomarker of breast cancer (BC) patients under 35 years old[J]. J Clini Oncol, 2020, 38 15_suppl: e12569-e12569.DOI: 10.1200/JCO. 2020.38.15_suppl.e12569.

[7] 王立泽,李金锋,王天峰,等.发病年龄对乳腺癌保留乳房治疗后长期生存的影响[J].中华外科杂志,2021,59(2):127-133.DOI:10.3760/cma.j.cn112139-20200807-00617.

[8] Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J]. Int J Cancer, 1983,31(1):13-20. DOI: 10.1002/ijc.2910310104.

[9] Seo SH, Kim KH, Oh SH, et al. Ki-67 labeling index as a prognostic marker in advanced stomach cancer[J]. Ann Surg Treat Res, 2019,96(1):27-33. DOI: 10.4174/astr.2019.96.1.27.

[10] 李英华,杨丽春,丁云川.乳腺浸润性导管癌超声征象与ER、PR、c-erbB2表达的相关性研究[J].临床超声医学杂志,2008,10(7):452-454.DOI:10.3969/j.issn.1008-6978. 2008.07.006.

[11] Wu Q, Ma G, Deng Y, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis[J]. Front Oncol, 2019,9:1068. DOI: 10.3389/fonc.2019.01068.

[12] Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis[J]. Breast Cancer Res, 2011,13(2):R22. DOI: 10.1186/bcr2834.

[13] Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer[J]. Gene, 2006,366(1):2-16. DOI: 10.1016/j.gene.2005. 10.018.

[14] Crozier JA, Advani PP, LaPlant B, et al. N0436 (Alliance): a phase ii trial of irinotecan with cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy[J]. Clin Breast Cancer, 2016,16(1):23-30. DOI: 10.1016/j.clbc.2015.08.002.

[15] Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors[J]. Nature, 2016,534(7605):129-132. DOI: 10.1038/nature17960.

[16] 宋翔,于志勇.三阴性乳腺癌抗EGFR靶向治疗研究进展[J].中华肿瘤防治杂志,2018,25(3):215-220.DOI:10.16073/j.cnki.cjcpt.2018.03.014.

[17] 苗兰芳,雷瑞雪,杨海军.EGFR、CK5/6在三阴性乳腺癌中的表达及临床病理意义[J].国际医药卫生导报,2016,22(24):3789-3791.DOI:10.3760/cma.j.issn.1007-1245. 2016.24.023.

[18] Jain KK . Biomarkers of Cancer[M]. Springer New York, 2014.

[19] Stănculescu D, Mărgăritescu C, Stepan A, et al. E-cadherin in gastric carcinomas related to histological prognostic parameters[J]. Rom J Morphol Embryol, 2011,52(3 Suppl):1107-1112.

[20] Mittendorf EA, Vila J, Tucker SL, et al. The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment[J]. JAMA Oncol, 2016,2(7):929-936. DOI: 10.1001/jamaoncol. 2015.6478.

[21] 王国聪,许凤锐,李健斌,等.乳腺癌新辅助治疗Neo-Bioscore评价体系与无病生存的相关性[J].中华医学杂志,2017,97(30):2349-2352.DOI:10.3760/cma.j.issn.0376-2491.2017.30.007.

[22] Hasegawa Y, Matsubara N, Kogawa T, et al. Neo-bioscore in guiding post-surgical therapy in patients with triple-negative breast cancer who received neoadjuvant chemotherapy[J]. In Vivo, 2021,35(2):1041-1049. DOI: 10.21873/invivo.12348.

[23] Suo S, Cheng F, Cao M, et al. Multiparametric diffusion-weighted imaging in breast lesions: association with pathologic diagnosis and prognostic factors[J]. J Magn Reson Imaging, 2017,46(3):740-750. DOI: 10.1002/jmri.25612.

[24] 焦武,姚峰,汪雯洁.Neo-Bioscore评分在乳腺癌新辅助化疗预后评估中的价值[J].肿瘤学杂志,2019,25(5):432-435.DOI:10.11735/j.issn.1671-170X.2019.05.B011.

[25] Yang YF, Liao YY, Li LQ, et al. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer[J]. Pathol Res Pract, 2013, 209(12):797-802. DOI: 10.1016/j.prp.2013.08.012.

乳腺癌中Ki-67、EGFR及E-cad表达及其对预后的影响研究

Expressions of Ki-67, EGFR, and E-cad in breast cancer and their effects on prognosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

[1]	陈楚君, 陈玲, 施景华, 许婉珠, 罗泽槟. 乳腺癌患者术后患肢淋巴水肿延迟就医的质性研究 [J]. 国际医药卫生导报, 2022, 28(9): 1247-1250.
[2]	袁琛烨, 李玉群. 慢病自我管理模式应用于乳腺癌患者术后淋巴水肿中的效果评价[J]. 国际医药卫生导报, 2022, 28(8): 1126-1130.
[3]	吴雪婷, 陈晓仪, 吴怡雯, 蔡泳娜, 肖明月, 陈凤娟, 韩嫱琳, 邱少东, 祝志敏, 陈菲. 超声影像组学在乳腺癌中应用的研究进展[J]. 国际医药卫生导报, 2022, 28(4): 484-487.
[4]	袁琛烨, 周之音. 基于智慧医疗系统的管理模式预防乳腺癌患者术后淋巴水肿的效果观察 [J]. 国际医药卫生导报, 2022, 28(3): 336-340.
[5]	方涌文, 方键蓝, 刘镖水, 姚文燕, 林晓生, 林承光, 肖亮杰. 模拟复位验证在乳腺癌患者调强放疗中应用价值的探讨[J]. 国际医药卫生导报, 2022, 28(11): 1482-1485.
[6]	杨杨, 李建华, 程瑶, 朱瑞萍. 乳腺癌病理诊断中免疫组织化学检测的临床效果分析[J]. 国际医药卫生导报, 2022, 28(11): 1492-1494.
[7]	康梦玲, 李良芳, 刘冬冬, 黄乐珍. 围绝经期乳腺癌患者体质、Kupperman评分及其治疗的调查研究[J]. 国际医药卫生导报, 2022, 28(11): 1495-1499.
[8]	慈明伟, 刘楠, 高璐璐. 奥希替尼+培美曲塞及贝伐单抗三联化疗对EGFR突变型NSCLC的疗效分析[J]. 国际医药卫生导报, 2022, 28(10): 1418-1421.
[9]	兰国玉, 汤守元, 黄耿, 朱钟钟, 李新明, 罗海平, 姜进平. miR-4795-3p通过靶向EGFR抑制胃癌细胞的增殖和侵袭[J]. 国际医药卫生导报, 2022, 28(1): 42-45.